Tin-mesoporphyrin in the treatment of refractory hyperbilirubinemia due to Rh incompatibility

Maisels, M. Jeffrey; Yang, Hyeong Tae

doi:10.1038/jp.2012.45

Cited by 7 publications

(5 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to the blockade of heme metabolism and reduction of the free iron status of cells, metalloporphyrins might affect hemoproteins and other enzymes, including cytochrome P450 (78). Rosenfeld et al concluded that SnMP combined with phototherapy was superior to phototherapy alone in neonates with significant IHB due to hemolysis (79), consistent with the results of another study (80). The efficacy, toxicity, and long-term benefits of metalloporphyrins are not clear, and further studies are needed in this regard (24,78,81).…”

Section: Metalloporphyrinsmentioning

confidence: 57%

Recent Advances in Adjuvant Pharmacotherapy for Neonatal Indirect Hyperbilirubinemia: A Narrative Review

Nouri

Zarkesh

2023

J Compr Ped

View full text Add to dashboard Cite

Context: Hyperbilirubinemia is a common cause for diagnostic work-up and therapeutic intervention in neonates and needs a convenient, quick, and safe treatment modality. Phototherapy is the most common treatment for neonatal jaundice; however, complementary treatment is still needed. Despite the identification of the enzymatic pathways of bilirubin catabolism, few pharmacological interventions have been found to be effective in reducing bilirubin, along with traditional phototherapy. This review was conducted to evaluate recent pharmacotherapies as adjuvants to phototherapy for the treatment of neonatal indirect hyperbilirubinemia (IHB). Evidence Acquisition: This study was carried out through a literature search with the keywords of Infant, Newborn, and Indirect Hyperbilirubinemia, combined with Drug Therapy, in PubMed, Scopus, International Statistical Institute, Web of Science, Cochrane, and Embase databases. This study included relevant articles (i.e., randomized controlled trials, observational studies, guidelines, and reviews) written in English and published between 2012 - 2022. Results: This narrative review first assessed the relevant articles to define IHB and its etiology. Then, the efficacy and side effects of recent pharmacologic agents as adjuvants to phototherapy were discussed. Additionally, this study reviewed the efficacy and safety of drugs prescribed to neonates to prevent jaundice. Conclusions: The best drug for adjuvant pharmacotherapy, in addition to phototherapy, for neonatal jaundice has not still been identified. The use of probiotics, prebiotics, synbiotics, and ursodeoxycholic acid (UDCA) in adjuvant to phototherapy has been recently increasing, and beneficial results were observed in most studies. The use of agar, charcoal, fibrate, and phenobarbital had a minor therapeutic role in recent years. There were conflicting results about the efficacy of herbal agents in neonatal jaundice. The use of intravenous immunoglobulin (IVIG), metalloporphyrin, and albumin is also limited to severe or immune-related IHB cases. The prescription of the aforementioned drugs sometimes had different results. Therefore, further research in this regard is necessary.

show abstract

Section: Metalloporphyrinsmentioning

confidence: 57%

Recent Advances in Adjuvant Pharmacotherapy for Neonatal Indirect Hyperbilirubinemia: A Narrative Review

Nouri

Zarkesh

2023

J Compr Ped

View full text Add to dashboard Cite

show abstract

“…Rather, a prolonged sustained low level of bilirubin was observed, similar to the animal study [ 15 ], although still significantly lower than the control group [ 35 , 37 ]. This inferred that the profound inhibitory effect of Sn-MP is only evident by 24 to 48 hours with the initial sharp decline [ 38 ], but significant difference in bilirubin levels compared to the control group occurs only at three to five days posttreatment. Hence, further study with intravenous administration is also required to avoid the confounding effect of the route of administration in finding the exact efficacy of Sn-MP.…”

Section: Discussionmentioning

confidence: 99%

“…Reports with safety concerns Drummond et al [18] Hintz et al [23] Drummond and Kappas [19] DeSandre et al [20] Fort and Gold [24] Morioka et al [21] Wong et al [22] Vreman et al [25] Rosenfeld et al [35] Rosenfeld et al [36] Bhutani et al [37] Maisels and Yang [38] Valaes et al [39] Kappas et al [40] Martinez et al [41] Valaes et al [42] Kappas et al [43] Case reports: Kappas et al [32] Rubaltelli et al [33] Galbraith et al [34] Maisels and Yang [38]…”

Section: Reports Favoring Efficacymentioning

confidence: 99%

Efficacy and Safety Concerns with Sn-Mesoporphyrin as an Adjunct Therapy in Neonatal Hyperbilirubinemia: A Literature Review

Poudel

Adhikari

2022

International Journal of Pediatrics

View full text Add to dashboard Cite

Neonatal hyperbilirubinemia is a frequently observed clinical situation that, sometimes, may result in complications ranging from mild neurodevelopment impairment to serious outcome of kernicterus. The rationale logic of heme oxygenase enzyme inhibition to lower bilirubin levels is intriguing. In compliance with that rationale, metalloporphyrin was discovered. After successful results in in-vitro and animal studies, tin mesoporphyrin is now under phase II clinical trial to test for preventive and therapeutic efficacy in unconjugated hyperbilirubinemia. This review evaluates in-vitro studies, animal studies, and clinical trials for the efficacy and safety of tin analogues of metalloporphyrin. Few alternatives to metalloporphyrins are also available, synchronizing with the same rationale logic of inhibition of bilirubin production, which need further research.

show abstract

“…The Zn-protoporphyrin-lipid treatment has also been found to be effective in inhibition of hemoxygenase and reduction of hyperbilirubinemia in newborn mouse models [73]. The combination of phototherapy and SnMP also effectively reduced the duration and need of repeated phototherapy for the treatment of hyperbilirubinemia in infants with hemolytic disease due to Rh incompatibility [74].…”

Section: Recent Advancements In the Treatment Of Hyperbilirubinemiamentioning

confidence: 99%

Neonatal hyperbilirubinemia: Background and recent literature updates on the diagnosis and treatment

Nawaz

Aslam

Rehman

2021

PhysInt

View full text Add to dashboard Cite

Hyperbilirubinemia or jaundice has been studied by many researchers because of its diverse causes and potential for toxicity especially in the neonate but to a lesser extent beyond the neonate as well. Several studies have been performed on the normal metabolism and metabolic disorders of bilirubin in last decades of the 20th century. The recent advancement in research and technology facilitated for the researchers to investigate new horizons of the causes and treatment of neonatal hyperbilirubinemia. This review gives a brief introduction to hyperbilirubinemia and jaundice and the recent advancement in the treatment of neonatal hyperbilirubinemia. It reports modifications in the previously used methods and findings of some newly developed ones. At present, ample literature is available discussing the issues regarding hyperbilirubinemia and jaundice, but still more research needs to be done.

show abstract

Tin-mesoporphyrin in the treatment of refractory hyperbilirubinemia due to Rh incompatibility

Cited by 7 publications

References 10 publications

Recent Advances in Adjuvant Pharmacotherapy for Neonatal Indirect Hyperbilirubinemia: A Narrative Review

Recent Advances in Adjuvant Pharmacotherapy for Neonatal Indirect Hyperbilirubinemia: A Narrative Review

Efficacy and Safety Concerns with Sn-Mesoporphyrin as an Adjunct Therapy in Neonatal Hyperbilirubinemia: A Literature Review

Neonatal hyperbilirubinemia: Background and recent literature updates on the diagnosis and treatment

Contact Info

Product

Resources

About